CirQuest Labs   Report issue

For profit Phase 1 Phase 4
Founded: Memphis TN United States (2008)

Organization Overview

First Clinical Trial
2017
NCT03027934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CirQuest Labs | CirQuest Labs, LLC

Active Ingredients

Drugs in Phase 4 Trials (2)

prasugrel (effient) (1 trial)

ticagrelor (brilinta) (1 trial)

Drugs in Phase 1 Trials (1)

Zalunfiban (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Disease (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3